Is regorafenib (Belvango) a targeted drug or a chemotherapy drug and its mechanism of action?

Regorafenib is an oral, small molecule, multi-target tyrosine kinase inhibitor, mainly used to treat solid tumors such as advanced colorectal cancer, gastrointestinal stromal tumors (GIST), and hepatocellular carcinoma (HCC). It is a targeted therapy drug rather than a traditional chemotherapy drug. Unlike chemotherapy drugs that directly kill rapidly dividing cells, targeted drugs regulate tumor cell proliferation, angiogenesis and the tumor microenvironment by inhibiting specific signaling pathways or molecular targets, thereby preventing tumor development.

The core mechanism of action of regorafenib is multi-target inhibition. It can simultaneously inhibit vascular endothelial growth factor receptor (VEGFR1-3), platelet-derived growth factor receptor (PDGFR), stem cell factor Receptor (KIT), RAFkinase and TIE2 and other key molecules. These molecules play important roles in tumor angiogenesis, proliferation, and metastasis. By blocking these signaling pathways simultaneously, regorafenib can inhibit new blood vessel formation, reduce tumor blood supply, and directly interfere with tumor cell growth and survival.

Compared with traditional chemotherapy, the targeting effect of regorafenib is more precise. Chemotherapy drugs usually lack selectivity and can simultaneously damage normal rapidly dividing cells, such as bone marrow cells and digestive tract mucosal cells, leading to side effects such as hair loss, nausea, and bone marrow suppression. Regorafenib targets specific tyrosine kinases and has relatively controllable side effects. Common adverse reactions include hand-foot syndrome, hypertension, fatigue, and abnormal liver function, but they can be managed through dose adjustment or symptomatic treatment.

In general, regorafenib is a targeted drug. Its mechanism of action inhibits tumor-related signaling pathways through multiple targets to achieve the effect of inhibiting tumor proliferation, angiogenesis and metastasis. It provides an important treatment option in addition to chemotherapy for advanced patients with colorectal cancer, GIST and hepatocellular carcinoma. It is especially suitable for patients who are resistant to traditional chemotherapy or cannot tolerate chemotherapy. The precision and controllability of targeted therapy make regorafenib play a unique clinical value in the management of advanced solid tumors.

Reference link:https://www.drugs.com